Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells

This publication has 59 references indexed in Scilit:

• Dopamine agonist monotherapy in Parkinson's disease
  The Lancet, 2002
• Mitochondrial and nonmitochondrial reduction of MTT: Interaction of MTT with TMRE, JC‐1, and NAO mitochondrial fluorescent probes
  Cytometry, 2002
• Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
  Nature Reviews Neuroscience, 2001
• Neuroprotective effects of D3 dopamine receptor agonists
  Parkinsonism & Related Disorders, 2001
• Is There a Rationale for Neuroprotection Against Dopamine Toxicity in Parkinson's Disease?
  Cellular and Molecular Neurobiology, 2001
• Cell Survival Promoted by the Ras-MAPK Signaling Pathway by Transcription-Dependent and -Independent Mechanisms
  Science, 1999
• Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D_2(long), D₃ and D_4.4 receptors expressed in Chinese hamster ovary cells
  British Journal of Pharmacology, 1999
• Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
  Cell, 1999
• Pramipexole Reduces Reactive Oxygen Species Production In Vivo and In Vitro and Inhibits the Mitochondrial Permeability Transition Produced by the Parkinsonian Neurotoxin Methylpyridinium Ion
  Journal of Neurochemistry, 1998
• Serine 133-Phosphorylated CREB Induces Transcription via a Cooperative Mechanism That May Confer Specificity to Neurotrophin Signals
  Molecular and Cellular Neuroscience, 1995